-- Mayne Pharma Group (ASX:MYX) reported unaudited fiscal third-quarter revenue of AU$85.2 million, up 1% from AU$84.3 million a year earlier, according to a Wednesday filing with the Australian bourse.
The company also reported underlying loss before interest, taxes, depreciation, and amortization of AU$1.4 million, an improvement from a AU$3.3 million loss in the year-ago period.
Mayne Pharma said it continues to evaluate capital allocation strategies, including a potential on-market share repurchase.